
**"Shifting Gears" Towards Palliative Therapy for Recurrent Breast Cancer** 

#### Mohammad Jahanzeb, MD, FACP

Van Vleet Endowed Professor of Medical Oncology Chief, Division of Hematology-Oncology University of Tennessee Cancer Institute

> NCCN National Comprehensive Cancer Network®

#### Diminishing Response rates in Subsequent Lines of Therapy



The interrelationship of therapies with curative and palliative intent


**Curative / life-prolonging therapy** 

**Presentation** 

Relieve suffering (palliative care)

Death

NCCN National Comprehensive Cancer Network®



## **Shifting Emphasis of Care**

**DURING ANTITUMOR TREATMENT**:


- Cure of disease
- Avoidance of premature death
- Maintenance or improvement in function
- Prolongation of life

- AFTER STOPPING ANTITUMOR TREATMENT:
- Relief of suffering
- Quality of life
- Staying in control
- A comfortable death
- Support for families and loved ones



Practice Guidelines in Oncology – v.1.2007

#### Palliative Care



<sup>a</sup>Management of any patient with positive screening requires a care plan developed by a interdisciplinary team of physicians, nurses, mental health professionals, and chaplains.

<sup>b</sup>Oncologists should integrate palliative care into general oncology care for patients who meet screening criteria. Consultation/collaboration with a palliative care specialist/hospice team is recommended for patients with more complex issues.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2007, 06/04/07 © 2007 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. PAL-3

**5** steps for successful advance care planning **1.** Introduce the topic **2.** Engage in structured discussions **3.** Document patient preferences 4. Review, update **5.** Apply directives when need arises

> CCN National Comprehensive Cancer Network®

# **Breaking Bad News**

#### **Definition:**

Bad news is any news that seriously And adversely affects the patient's View of his or her future



# **Breaking Bad News**

- S Getting the SETTING right, P What the patient PERCEIVES, An INVITATION to share the news, Κ Giving the KNOWLEDGE. **EMPATHISING & EXPLORING** Ε the patient's emotions, and S
  - STRATEGY and SUMMARY.

National Comprehensive Cancer Network®

NC(

# **Breaking Bad News**

#### The Empathic Response

- 1. Identify the emotion (theirs or yours)
- 2. Identify the source of the emotion
- 3. Respond in a way that shows you have made that connection

You don't have to agree with the viewpoint You don't have to feel the emotion yourself

> CCN National Comprehensive Cancer Network®


# Palliative Care: Expanding the Options

Interdisciplinary care
Symptom control
Supportive care

NCCN Network®



#### PALLIATIVE CARE ASSESSMENT



#### Practice Guidelines in Oncology – v.1.2007 Palli

#### Palliative Care

BENEFIT/RISK OF ANTICANCER THERAPY								
ESTIMATED LIFE	INTERVENTION		REASSESSMENT					
Years Year to months	<ul> <li>Provide appropriate anticancer therapy as outlined in <u>NCCN disease-specific</u> <u>guidelines</u></li> <li>Discuss goals, benefits, and risks of anticancer therapy including possible effects on quality of life</li> <li>Clarify intent of anticancer therapy</li> <li>Provide evidence-based conventional anticancer therapy</li> <li>Offer clinical trials</li> <li>Provide appropriate prevention and management of symptoms caused by anticancer therapy</li> <li>Provide appropriate palliative care</li> </ul>	1	Satisfactory: • Adequate pain and symptom control • Reduction of patient/family distress • Acceptable sense of control • Relief of caregiver burden • Strengthened relationships • Optimized quality of life • Personal growth and enhanced meaning	Continue → anticancer therapy				
Months to weeks	<ul> <li>See above interventions</li> <li>Offer best supportive care including referral to palliative care or hospice</li> <li>Redirect goals and hopes to those that are achievable</li> <li>Provide guidance regarding anticipated</li> <li>Discontinue anticancer therapy</li> </ul>		Unsatisfactory →	<ul> <li>Change or discontinue anticancer therapy</li> <li>Review patient hopes about and meaning of anticancer therapy</li> </ul>	→ Ongoing reassessment			
Weeks to days (Dying patient)	<ul> <li>Intensify palliative care in preparation for death</li> <li>Provide guidance regarding anticipated dying process</li> <li>Focus on symptom control and comfort</li> <li>Foster patient participation in preparing loved ones</li> <li>Refer to palliative care/hospice team</li> </ul>		Unsatisfactory	<ul> <li>Intensify palliative care efforts</li> <li>Consult or refer to specialized palliative care</li> </ul>				

Note: All recommendations are category 2A unless otherwise indicated.

NCCN®

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2007, 06/04/07 © 2007 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. PAL-7

#### **Approach to Palliative Care** • Principles of symptom management Understand the pathophysiology Manage quickly; continuous & breakthrough dosing **Rationalize multisymptom management** • Coordination of care Patient, family education Interdisciplinary team Intended versus unintended effects **Terminal sedation requires consultation**

#### The TM EPEC-O Education in Palliative and End-of-life Care - Oncology Project

Emanuel LL, Ferris FD, von Gunten CF, Von Roenn J. EPEC-O: Education in Palliative and End-of-life Care - Oncology. © The EPEC<sup>™</sup> Project, Chicago, IL, 2005 NorthWestren University Feinberg School of Medicine Chicago, Illinois USA

The EPEC-O Curriculum is produced by the EPEC<sup>™</sup> Project with major funding provided by NCI, with supplemental funding provided by the Lance Armstrong Foundation.

## Common Symptoms in Terminal Cancer

- Pain
- Anorexia/Cachexia
- Fatigue
- Dyspnea
- Constipation
- Bowel Obstruction
- Anxiety/Depression

## **Selected Common Symptoms**

Pain
Anorexia
Fatigue
Depression

NCCN National Comprehensive Cancer Network®

#### Practice Guidelines in Oncology – v.1.2007 Palliative Care

PAIN							
ESTIMATED LIFE	INTERVENTION	REASSESSMENT					
Years Year to months Months to weeks	Treat according to NCCN Cancer Pain Guidelines reassessment	Satisfactory:         • Adequate pain and symptom control         • Reduction of patient/family distress					
Weeks to days (Dying patient) →	<ul> <li>Treat according to NCCN Cancer Pain Guidelines</li> <li>In addition: <ul> <li>Do not reduce dose of opioid solely for decreased blood pressure, respiration rate, or level of consciousness</li> <li>Maintain analgesic therapy; titrate to optimal comfort</li> <li>Recognize and treat opioid-induced neurotoxicity including hyperalgesia</li> <li>If opioid reduction is indicated, reduce by ≤ 50% per 24 h to avoid acute opioid withdrawal or pain crisis. Do not administer opioid antagonist</li> <li>Balance analgesia against reduced level of consciousness based on patient preference</li> <li>Modify routes of administration as needed (PO, IV, PR, subcutaneous, sublingual, transdermal) applying equianalgesic dose conversions</li> <li>Consider sedation for refractory pain (See PAL-29).</li> </ul> </li> </ul>	<ul> <li>Acceptable sense of control</li> <li>Relief of caregiver burden</li> <li>Strengthened relationships</li> <li>Optimized quality of life</li> <li>Personal growth and enhanced meaning</li> <li>Unsatisfactory</li> <li>Unsatisfactory</li> </ul>					

#### See Special Palliative Care Interventions: Imminently Dying Patient (PAL-28)

NCCN®

See List of Symptoms in Palliative Care Table of Contents

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

**Pain Pathophysiology**  Acute pain Identified event, resolves days-weeks **Usually nociceptive** • Chronic pain Cause often not easily identified, multifactorial Indeterminate duration **Nociceptive and / or neuropathic** 

Wolf CJ. Ann Intern Med. 2004.

## **Nociceptive pain**

Direct stimulation of intact nociceptors
 Transmission along normal nerves
 Somatic
 Easy to describe, localize
 Visceral
 Difficult to describe, localize

## **Neuropathic pain**

- Disordered peripheral or central nerves
- Compression, transection, infiltration, ischemia, metabolic injury
- Varied types

Peripheral, deafferentation, complex regional syndromes

Wolf CJ. Ann Intern Med. 2004.

WHO 3-step				
	Ladder	3 severe		
	2 moderate	Morphine Hydromorphone Methadone		
	A/Codeine	Levorphanol		
1 mild	A/Hydrocodone	Fentanyl		
	A/Oxycodone	Oxycodone		
ASA	A/Dihydrocodeine	± Adjuvants		
Acetaminophen	Tramadol			
NSAID's	± Adjuvants			
± Adjuvants		WHO Geneva, 1996.		


Non-pharmacological pain management . .

Neurostimulation **TENS**, acupuncture Anesthesiological **Nerve block** Surgical Cordotomy • Physical therapy **Exercise**, heat, cold Non-pharmacological pain management

 Psychological approaches **Cognitive therapies** (relaxation, imagery, hypnosis) **Biofeedback Behavior therapy, psychotherapy**  Complementary therapies Massage Art, music, aroma therapy

#### Placebos

#### No role for placebos to assess or treat pain!



## **Nociceptive pain**

Tissue injury apparent
 Management
 Opioids
 Adjuvant / coanalgesics

### **Neuropathic pain**

 Pain may exceed observable injury
 Described as burning, tingling, shooting, stabbing, electrical
 Management Opioids

Adjuvant / coanalgesics often required

### Pain management

 Don't delay for investigations or disease treatment

 Unmanaged pain => nervous system changes


Permanent damage

amplify pain

 Treat underlying cause (eg, radiation for a neoplasm)

#### **Anorexia and Cachexia**

Cachexia – wasting syndrome
↓ Lean tissue
↓ Performance status
Altered resting energy expenditure
↓ Appetite



Version 1.2007, 08/04/07 @ 2007 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

PAL-11

NCCN	Practice Guidelines in Oncology – v.1.2007	Palliative Ca	re		Palliative Care TOC MS, References
ESTIMATED LIFE	INTERVENTION	ANOREXIA/CACHEXIA	REASSESSMENT		
Years Year to months Months to weeks Weeks to days (Dying	<ul> <li>See Interventions (PAL-11)</li> <li>Assess importance of symptoms anorexia and cachexia to patient &gt; If important, consider short couting Treat for depression</li> <li>Recognize that suspension of nur support is a value-laden issue. C consultation with bioethicist or sy</li> <li>Inform patient and family of nature of disease, including the following</li> <li>Absence of hunger and thirst is the dying patient</li> <li>Nutritional support may not be in patients with advanced canc</li> <li>There are risks associated with support and hydration, including infection, and hastened death</li> <li>IV hydration may increase excre- metabolites providing benefit to Symptoms like dry mouth can be measures, eg, mouthcare, small</li> </ul>	t and family urse of corticosteroids tritional onsider piritual counselor ral history g points: s normal in metabolized er nutritional ng fluid overload, etion of drug o the patient be treated with local	Satisfactory: • Adequate anorexia/ cachexia symptom control • Reduction of patient/family distress • Acceptable sense of control • Relief of caregiver burden • Strengthened relationships • Optimized quality of life • Personal growth and	Continue to treat and monitor symptoms and quality of life to determine whether status warrants change in strategies	→ Ongoing reassessment
	<ul> <li>Withdrawal of IV or nasogastric</li> </ul>	: (NG) tube feeding is	• int	tensify palliative	

Withdrawal of IV or nasogastric (NG) tube feeding is ethically permissible in this setting. It will not cause exacerbation of symptoms and may improve some symptoms

- Focus on patient goals and preferences
- Provide family with alternate ways of caring for the patient

See Special Palliative Care Interventions; Imminently Dying Patient (PAL-28) See List of Symptoms in Palliative Care Table of Contents

care efforts

 Consult or refer to specialized

palliative care

Guidelines Index

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Unsatisfactory

Anorexia/Cachexia: Pathophysiology

- Chronic inflammation
- Metabolic changes
- Lipolytic / proteolytic substances
- Hormonal changes
- Role of neurotransmitters
- Cytokine impact on hypothalamus

Todorov P, et al. *Nature*, 1996. Todorov P, et al. *Cancer Research*, 1998. Zigman JM, et al. *Endocrinology*, 2003. Balkwill F, et al. *Lancet*, 2001.

## Anorexia/Cachexia: Assessment

Appetite / weight loss history
Identify reversible causes
Physical signs of wasting
Biochemical markers
Radiographic studies as indicated

## **Management of Anorexia**

• Dexamethasone

Megestrol acetate

Tetrahydrocannabinol (THC)

Androgens

Loprinzi CL, et al. *JCO*, 1999. VonRoenn JH, et al. 2003. Moertel CG, et al. *Cancer*, 1974.

## **Management of Cachexia**

Investigational Anabolic steroids **Omega-3-fatty acids** Amino acids **NSAIDs Multi-vitamins** Exercise

> Von Roenn JH, et al. *ASCO*, 2003. Jatoi A, et al. *ASCO*, 2003. Fearon KCH, et al. *Gut*, 2003. McMillan DC, et al. *Br J Ca*, 1999.



Definition

- Persistent sense of tiredness
  Interferes with function
- Unrelieved by rest

Cella D, Peterman A, et al. Oncology, 1998.

# Fatigue

Epidemiology

- High prevalence-varies with stage and primary
- High impact
- Patterns of fatigue

Chemotherapy

Radiotherapy

Volgelzang N, Breitbart W, et al. Semin Hematal, 1997. Cella D, Peterman A. Oncology, 1998. Stone P, Richardson A, et al. Ann Oncol, 2000. Schwartz AL, Nail LM, et al. Cancer Invest, 2000.

## Fatigue: Pathophysiology

Multifactorial

Abnormal energy metabolism

Increased cytokine production

Contributing factors

Depression

**Sleep disorders** 

**Muscular dysfunction** 

Fatigue: Assessment Subjective; 0-10 rating scale 4-6 = moderate fatigue 7-10 = severe fatigue • Fatigue history • Current medications Associated symptoms/Comorbidities Malnutrition / Deconditioning

Mock V, Atkinson, et al. NCCN, 2003.

### Fatigue: Management

**Treatable etiologies** Anemia Depression • Pain Hypothyroidism • Hypogonadism

#### Fatigue: Management

Non-pharmacologic therapies...

- Educate patterns of fatigue
- Clarify role of underlying illness, treatment
- Optimize fluid, electrolyte intake, nutrition
- Physical activity/Energy conservation
- Involve other disciplines

# Fatigue: Pharmacologic Management

Methylphenidate
Dexamethasone, prednisone
Modafinil

Bruera E. *Cancer Treatment Rep*, 1985. Bruera E, et al. *JCO*, 2004. Rammohan KW, et al. *J Neurol Neurosurg Psychiatry*, 2002.

# Depression

- Depressed mood
- Anhedonia loss of interest or pleasure
- > 2 weeks
- Prevalence: up to 58% of cancer patients
- Untreated, associated with poor prognosis
- Knowledge of true extent of disease and prognosis do not lead to depression or

advarga ollicomag

## **Symptoms of Depression-1**

Irritability

Changes in

**Appetite or weight** 

Sleep

**Psychomotor activity** 

Decreased energy

 Worthlessness, helplessness, hopelessness

#### • Guilt

## **Symptoms of Depression-2**

- Difficulty thinking, concentrating, making decisions
- Suicidal ideation or wishes to hasten death
- Somatic symptoms often not helpful in this population

### **Depresssion: Risk Factors-1**

Poorly controlled pain
 Progressive physical impairment
 Advanced disease
 Medications

 Steroids
 Chemotherapeutics

## **Depresssion: Risk Factors-2**

• Particular diseases Pancreatic, breast, lung, mets to nervous system • Younger age Spiritual pain Risk factors in general population **Prior Hx, family Hx, social stress** Suicide attempts, substance use

## **Depression: Pathophysiology**

Involved neurotransmitters
 Norepinephrine
 Serotonin
 Dopamine
 Genetics

Environmental influences

#### **Depression: Assessment**

Assess for signs and symptoms noted above
 Do you feel depressed most of the time?
 Family observations
 Screening tools

#### **Depression: Assessment**

Differentiate between
 Grief reactions
 Adjustment disorders
 Delirium, particularly hypoactive
 Dementia

 Consult with mental health professionals

#### **Depression: Management**

- Counseling
- Complementary therapies
- Pharmacotherapy
- Combinations are best

 Lack of improvement within weeks suggests more aggressive therapy or psychiatry consult needed

## **Complementary therapies**

- Relaxation
- Distraction
- Guided imagery
- Meditation
- Massage therapy
- Aromatherapy
- Self-hypnosis

- Exercise
- Sunlight

Depression: Pharmacotherapy

Tricyclic antidepressants
 SSRIs

 Preferred as less adverse effects

 Psychostimulants
 Other antidepressants

**Depression: Pharmacotherapy** • Choose by time to effect **Days – psychostimulants** Weeks / months – SSRIs, other antidepressants Start dosing low, titrate slowly Consider consultation



	AFTER DEATH CARE	
	For family and caregivers:	
A "good death": ● Free from avoidabl distress and suffering for patients, families, and caregivers ● In general accord with patient's and family's wishes ● Reasonably consistent with clinical, cultural, and ethical	<ul> <li>Immediate after death care</li> <li>Remove implanted devices</li> <li>Ensure culturally sensitive, respectful treatment of the body</li> <li>Provide family time with the body</li> <li>Address survivor concerns about organ donation and/or autopsy</li> <li>File death certificate, complete forms and provide necessary information for funeral director</li> <li>Offer guidance regarding normal bereavement process</li> <li>Inform other health care providers of patient's death</li> <li>Bereavement support</li> <li>Formally express condolences on patient's death (eg, card, call, or letter)</li> <li>Refer to appropriate bereavement services within the institution or in the community</li> <li>Attend debriefing meeting with family if family desires one</li> <li>Discuss cancer risk assessment and modification with family members</li> </ul> For health care professionals General: <ul> <li>Legitimize discussion of personal issues that impact on patient care</li> <li>Create climate of safety for discussion of patient deaths</li> <li>Provide regular opportunities for reflection and remembering for staff through memorial ritual Post-death: <ul> <li>Review medical issues related to patient death</li> <li>Explore concerns and questions regarding quality of patient care</li> <li>Review family emotional responses to patient death</li> <li>Include nurses, nursing assistants, physician team members (including med students, residents, fellows), social work, chaplaincy as appropriate</li> </ul></li></ul>	

	Back to Palliative Care	
Note: All recommendations are category 2A unless otherwise indicated.	Table of Contents	
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation	n in clinical trials is especially encouraged.	

## **Summary and Conclusions**

- Need to 'shift gears' when tumor is no longer the target
- There is a systematic way to break bad news to the patient
- Most symptoms of terminal cancer are manageable
- NCCN palliative and supportive care guidelines are a useful and accessible tool for the practitioner